SEC Form 4 · accession 0001179110-18-008436
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher P Leamon
Officer — Vice President of Research
Period of report
Jun 12, 2018
Accepted (ET)
Jun 13, 2018 · 3:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 12, 2018 | S | 13,089 | $15.0552 | D | 130,381 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the sale of 13,089 shares in multiple transactions, ranging in price from $15.0000 to $15.1850, resulting in a weighted-average sale price per share of $15.0552. The reporting person will provide, upon request by SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.